AsclepiX Therapeutics, Inc. — Form D/A

AsclepiX Therapeutics, Inc. of Bethesda, MD, a company, filed a Form D amendment with the SEC on 2019-06-17. The offering totals $10.0M, of which $7.7M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (25)

NameRoleLocation
Wendy PerrowDirectorBaltimore, MD
Wendy PerrowExecutive OfficerBaltimore, MD
Steven AltschulerDirectorWATERTOWN, MA
Chris GarabedianDirectorSan Francisco, CA
Robert DempseyExecutive OfficerBethesda, MD
Ben AskewDirectorBethesda, MD
Josh BarerDirectorBethesda, MD
Aleksander PopelExecutive OfficerBethesda, MD
Sapna SrivastavaDirectorBethesda, MD
Amir ShojaeiExecutive OfficerBethesda, MD
Niranjan PandeyExecutive OfficerBethesda, MD
Jill TierneyExecutive OfficerBethesda, MD
Jordan GreenDirectorBethesda, MD
Jordan J GreenDirectorPorte Vedra Beach, FL
Jordan J GreenExecutive OfficerPorte Vedra Beach, FL
Joshua BarerDirectorRochester, MI
Sapna S SrivastavaDirectorBaltimore, MD
Aleksander S Popel, PhDDirectorBaltimore, MD
Aleksander S Popel, PhDExecutive OfficerBaltimore, MD
Kevin S Slawin, MDDirectorBaltimore, MD
Kevin S Slawin, MDExecutive OfficerBaltimore, MD
Steven S Altschuler, MDDirectorBaltimore, MD
Joshua S BarerDirectorBaltimore, MD
Aleksander Popel, PhDDirectorBaltimore, MD
Kevin Slawin, MDDirectorBaltimore, MD

Other filings by this issuer (4)

FiledFormOfferingSold
2024-04-26D$12.5M$10.0M
2020-06-11D$35.0M$10.0M
2018-10-25D$7.5M$3.9M
2017-02-09D$1.0M$175K

More